Published in Ther Clin Risk Manag on June 26, 2014
Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol (2015) 0.89
Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators Inflamm (2016) 0.83
Development and novel therapeutics in hepatocellular carcinoma: a review. Ther Clin Risk Manag (2016) 0.79
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Hepatitis C: the clinical spectrum of disease. Hepatology (1997) 3.94
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology (2007) 3.73
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (2014) 2.83
Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol (2011) 2.40
Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol (2012) 2.34
Antiviral strategies in hepatitis C virus infection. J Hepatol (2012) 2.25
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol (2012) 2.14
Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology (1997) 1.96
Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci (1998) 1.90
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother (2012) 1.85
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology (2013) 1.84
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol (2007) 1.73
Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol (2011) 1.63
Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Curr Opin Investig Drugs (2009) 1.57
Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol (2012) 1.53
Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver (2002) 1.48
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol (2013) 1.47
Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol (2013) 1.45
Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World J Gastroenterol (2012) 1.30
Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology (2013) 1.24
Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol (2013) 1.21
Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother (2012) 1.16
Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther (2013) 1.13
The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs (2010) 1.10
Risk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: results from the hepatitis surveillance system in Italy. J Hepatol (2001) 1.09
The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol (2005) 1.08
A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem (2013) 1.03
Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol (2007) 1.02
Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Antimicrob Agents Chemother (2012) 1.01
Hepatitis B in pregnancy. World J Gastroenterol (2012) 1.00
Does HIV infection favor the sexual transmission of hepatitis C? Sex Transm Dis (2001) 0.98
Treating chronic hepatitis B: today and tomorrow. Curr Med Chem (2006) 0.98
Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hepat (2013) 0.95
Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection. Expert Opin Investig Drugs (2014) 0.95
Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res (2008) 0.93
Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples. Intervirology (2013) 0.93
Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infect Dis (2012) 0.93
Elucidating novel hepatitis C virus-host interactions using combined mass spectrometry and functional genomics approaches. Mol Cell Proteomics (2013) 0.92
Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol (2013) 0.92
Association of tattooing and hepatitis C virus infection: a multicenter case-control study. Hepatology (2013) 0.92
Myasthenia gravis during low-dose IFN-alpha therapy for chronic hepatitis C. J Interferon Cytokine Res (2001) 0.91
Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol (2009) 0.91
Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A. Curr Med Chem (2014) 0.88
Safety of direct antiviral agents in real life. Dig Liver Dis (2013) 0.88
MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin Investig Drugs (2014) 0.88
Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis (2011) 0.88
A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided? Acta Diabetol (2007) 0.87
Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem (2001) 0.86
Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother (2012) 0.85
Concomitant interferon-alpha and chemotherapy in hepatitis C and colorectal cancer: a case report. In Vivo (2013) 0.85
Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection. Infection (2013) 0.84
Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus. Expert Rev Anti Infect Ther (2014) 0.83
The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor. Antivir Ther (2014) 0.83
Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol (2007) 0.83
A pill for HCV - myth or foreseeable future? Liver Int (2013) 0.83
Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis (2013) 0.82
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev Anti Infect Ther (2014) 0.82
Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. J Interferon Cytokine Res (2005) 0.81
Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study. Liver Int (2008) 0.81
Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial. J Clin Apher (2009) 0.81
Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother (2013) 0.81
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir Ther (2013) 0.81
Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Ann Hepatol (2013) 0.80
Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells. J Clin Virol (2013) 0.80
Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PLoS One (2014) 0.80
Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem (2009) 0.79
Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol (2010) 0.79
A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C. Hepat Mon (2013) 0.79
Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era. Rev Recent Clin Trials (2014) 0.79
Acute hepatitis C in patients undergoing hemodialysis: experience with high-dose interferon therapy. Minerva Urol Nefrol (2013) 0.78
Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection. J Family Community Med (2013) 0.78
Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin Investig Drugs (2014) 0.78
A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis. J Clin Gastroenterol (2009) 0.77
HCV-related autoimmune disorders in HCV chronic infection. Clin Ter (2013) 0.77
Human platelet antigen-3 genotype predicts platelet count in patients with HCV infection. In Vivo (2013) 0.76
Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters? Infez Med (2014) 0.76
ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection. J Hepatol (2013) 0.76
Pernicious anemia during IFN-alpha treatment for chronic hepatitis C. J Interferon Cytokine Res (2003) 0.76
Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature. Expert Opin Pharmacother (2013) 0.76